News | September 07, 2021
Indian Pharmaceutical Market grew by 17.7 per cent in August
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Plasmacluster technology significantly inactivates SARS-CoV-2 contained in adherent saliva in an environment with 60% humidity where the physiological protective function is maintained
At present 18 per cent of the local pharmaceutical market is under government's price control
The segment delivered strong sales growth of 20% YoY
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
TAH is now undergoing regulatory clearance and final quality control procedures for the swab deployment in India, EU, Singapore, UK, US, Australia and others for COVID-19 testing
Demand normalisation post the second wave contributed to the steady growth
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
If approved it will bring a second source of MMR vaccine to the US market
Subscribe To Our Newsletter & Stay Updated
